Roth Capital affirms Ligand Pharma (Nasdaq: LGND) at Buy with a target price of $92 following an update from SAGE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE